Phase I trial of A1G4 anti-idiotype monoclonal antibody with Bacillus Calmette Guerin (BCG) adjuvant in high risk patients with ganglioside GD2 positive tumors
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Anti-idiotype GD2 cancer vaccine A1G4 (Primary)
- Indications Neuroblastoma; Osteosarcoma; Sarcoma
- Focus Adverse reactions; Pharmacodynamics
- 18 Jan 2013 Biomarkers information updated
- 22 Dec 2009 Actual end date (Jan 2005) added as reported by ClinicalTrials.gov.
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.